FLC Capital Advisors’s GSK GSK Stock Holding History

FLC Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$326K	Sell	6,228 -2,215	-26%	-$117K	0.05%	177
2026 Q1	$466K	Sell	8,443 -568	-6%	-$30.8K	0.08%	141
2025 Q4	$442K	Hold	9,011	–	–	0.08%	133
2025 Q3	$389K	Sell	9,011 -1,843	-17%	-$72K	0.08%	136
2025 Q2	$417K	Buy	10,854 +2,616	+32%	+$100K	0.09%	131
2025 Q1	$319K	Hold	8,238	–	–	0.07%	140
2024 Q4	$279K	Buy	+8,238	New	+$297K	0.06%	142
2023 Q2	–	Sell	-9,561	Closed	-$340K	–	151
2023 Q1	$340K	Buy	+9,561	New	+$334K	0.1%	113

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

FLC Capital Advisors's GSK Position: Q2 2026 in Review

FLC Capital Advisors reduced its GSK (GSK) stake by 26% in Q2 2026, selling an estimated $117K and leaving 6,228 shares worth $326K. The position accounts for 0.05% of the portfolio, ranked #177.

FLC Capital Advisors first reported a position in GSK in Q1 2023 and has held it in 8 quarters since. The position peaked at $466K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

FLC Capital Advisors held 6,228 shares of GSK worth $326K as of Q2 2026.
FLC Capital Advisors sold 2,215 GSK shares in Q2 2026, an estimated $117K.
GSK made up 0.05% of FLC Capital Advisors's portfolio in Q2 2026, its #177 holding.
FLC Capital Advisors first reported a position in GSK in Q1 2023 and has held it in 8 quarters since.
FLC Capital Advisors's GSK position peaked at $466K in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on FLC Capital Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.